In a report released today, Myles Minter from William Blair maintained a Buy rating on Ovid Therapeutics. The company’s shares opened today at $2.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Dianthus Therapeutics, and Argenx Se. According to TipRanks, Minter has an average return of 22.4% and a 57.54% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovid Therapeutics with a $3.40 average price target.
Based on Ovid Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.27 million and a GAAP net loss of $4.68 million. In comparison, last year the company earned a revenue of $169 thousand and had a net profit of $8.52 million
Read More on OVID:
Disclaimer & DisclosureReport an Issue
- Morning Movers: Apple shares slip following Jefferies downgrade
- Ovid Therapeutics prices private placement up to $175M in gross proceeds
- Ovid Therapeutics announces results for Phase 1 study of OV329
- Ovid Therapeutics Regains Nasdaq Compliance
- Ovid Therapeutics’ Promising Pipeline and Strategic Developments Justify Buy Rating
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
